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Abstract: The current work addresses the uniﬁ  cation of Electronic Health Records related to cervical cancer into a single 
medical knowledge source, in the context of the EU-funded ASSIST research project. The project aims to facilitate the 
research for cervical precancer and cancer through a system that virtually uniﬁ  es multiple patient record repositories, 
physically located in different medical centers/hospitals, thus, increasing ﬂ  exibility by allowing the formation of study 
groups “on demand” and by recycling patient records in new studies. To this end, ASSIST uses semantic technologies to 
translate all medical entities (such as patient examination results, history, habits, genetic proﬁ  le) and represent them in a 
common form, encoded in the ASSIST Cervical Cancer Ontology. The current paper presents the knowledge elicitation 
approach followed, towards the deﬁ  nition and representation of the disease’s medical concepts and rules that constitute the 
basis for the ASSIST Cervical Cancer Ontology. The proposed approach constitutes a paradigm for semantic integration of 
heterogeneous clinical data that may be applicable to other biomedical application domains.
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1. Introduction
Lack of uniformly structured data affects many areas of biomedical research, including drug discovery, 
systems biology, and individualized medicine, all of which rely heavily on integrating and interpreting 
data sets produced by different experimental methods at different levels of granularity, for which both 
the discovery and characterization is extremely difﬁ  cult.
1 The heterogeneity and “isolation” of bio-
medical resources has been identiﬁ  ed as the key research challenge,
2 towards the realization of trans-
lational medicine.
3
Genetic association studies constitute a signiﬁ  cant scientiﬁ  c approach that may lead to a more com-
prehensive and holistic insight on the origin of complex diseases,
4 aiming to identify association between 
one or more genetic variants (e.g. polymorphisms) and a trait, which might be some quantitative char-
acteristic, a discrete attribute, or a disease.
5 A genetic variant is genotyped in a population for which 
phenotypic information is available (such as disease occurrence, or a range of different trait values). If 
a correlation is observed between genotype and phenotype, there is an association between the variant 
and the disease or trait.
6
Although the number of studies elaborating on phenotype-genotype associations for common diseases 
is rapidly increasing, several studies show variation in the underlying association between genotype and 
outcome among the populations studied, resulting in questionable ﬁ  ndings. It is evident that reliable asso-
ciation studies require large sets of patient phenotypic and genotypic data, all provided in a structured 
format.
7 Thus, methodologies for data and system interoperability, assisted by the appropriate technologies, 32
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will alleviate the problems mentioned above. While 
standardisation of phenotypic data and clinical prac-
tices seems unrealistic, semantic annotation and 
transformations to widely agreed classification 
schemes may provide workable solutions.
In this regard, Semantic Web technologies,
8 
which are based on common formats that support 
aggregation and integration of data drawn from 
diverse sources, seem a key-enabler towards 
navigation and meaningful use of digital resources 
by employing automatic processes. The beneﬁ  ts 
promised by the Semantic Web include aggregation 
of heterogeneous data using explicit semantics, 
simpliﬁ  ed annotation and sharing of ﬁ  ndings, the 
expression of rich and well-deﬁ  ned models for data 
aggregation and search, easier reuse of data in 
unanticipated ways, and the application of logic to 
infer additional insights.
9 The potential of this 
technology endeavor has been particularly high-
lighted in biomedicine with initiatives such as the 
Semantic Web Health Care and Life Sciences Inter-
est Group (HCLSIG) established by W3C (World 
Wide Web Consortium), which is chartered to 
explore and support the use of Semantic Web tech-
nologies to improve collaboration, research and 
development, and innovation in the information 
ecosystem of the health care and life science 
domains. Especially in biomedicine, it is envi-
sioned that the use of Semantic Web technologies 
will improve the productivity of research, help 
raise the quality of health care, and enable scientists 
to formulate new hypotheses inspiring research 
based on clinical experiences.
Ontologies, considered as the backbone of the 
Semantic Web, play an important role in biomed-
ical research through a variety of applications.
10 
They provide the controlled vocabulary required 
for the annotation of biological datasets, the bio-
medical literature and patient records, facilitating 
the retrieval of and, more generally, access to 
information. Such standardization also facilitates 
the exchange of information and contributes to 
semantic interoperability among systems. By pro-
viding a representation of a domain, ontologies are 
also used in the mediation approach to integrating 
datasets.
11 Finally, many applications use ontolo-
gies as a source of computable domain knowledge, 
including natural language processing applications 
and decision support systems.
12 Ontologies are also 
critical to hypothesis generation and knowledge 
discovery in a data-driven approach to biomedical 
research.
13
The concept of supporting in a systematic way 
the conduction of multi-center association studies 
has been elaborated in ASSIST (Association Studies 
aSsisted by Inference and Semantic Technologies) 
by adopting inference and semantic technologies.
14 
ASSIST is an EU-funded research project that aims 
to facilitate the design and execution of genetic 
association studies on cervical precancer and cancer 
(CxPCa). Toward this goal, ASSIST provides the 
means for seamless integration and virtual uniﬁ  ca-
tion of distributed and heterogeneous CxPCa data 
repositories, as well as the underlying mechanisms 
to undertake the entire process of expressing and 
statistically evaluating medical hypotheses based 
on the collected data, in order to generate medically 
important associations. ASSIST aims to be used 
primarily by biomedical researchers for the identi-
ﬁ  cation of new markers of risk, diagnosis and prog-
nosis, and possibly treatment of cervical precancer 
and early cancer via the implementation of case-
control association studies.
Cervical cancer is an important cause of women 
mortality throughout the world. Current evidence 
suggests that speciﬁ  c subtypes of a certain virus, 
namely, the Human Papilloma Virus (HPV), cause 
genital infection that predisposes to cervical cancer 
development later in life.
15 Under research are other 
cofactors of cervical precancerous lesions. Tobacco 
use, number of sexual partners, number of deliver-
ies, use of hormonal contraception, are character-
istics that can put individuals at risk for CxPCa.
16 
Moreover, genetic polymorphisms, such as Methy-
leneTetraHydroFolate Reductase (MTHFR), p53 
codon 72, Glutathione-S-Transferase (GST) T1, 
GST M1, and cytochrome P1 (CYP1) A1, are cur-
rently under investigation about their role in the 
pathogenesis of this disease.
17–21
The current paper presents the knowledge 
elicitation approach followed towards the deﬁ  ni-
tion and representation of medical concepts related 
to diagnosis and disease severity that constitute the 
basis for the ASSIST CxPCa semantic model, 
emphasizing on the data uniﬁ  cation procedure 
applied in three busy clinical sites across Europe. 
The paper is structured as follows. First, the origin 
and nature of the CxPCa data repositories consid-
ered in ASSIST are described. Then, the major 
CxPCa semantic medical concepts elaborated in 
the knowledge engineering phase of the project are 
presented. The common coding towards the seman-
tic uniﬁ  cation of CxPCa data repositories is then 
introduced, as far as the major clinical interventions 33
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related to CxPCa are concerned. The approach 
followed to infer the disease severity based on 
semantic rules associating the clinical ﬁ  ndings of 
the abovementioned medical interventions is then 
elaborated, while aspects related to the implemen-
tation of the semantic model and an example usage 
scenario are presented. Finally, a discussion on 
related works as well as on the virtue of the 
proposed approach and its potential conclude 
the paper.
2. Materials and Methods
2.1. Cervical cancer data repositories
The ASSIST project aims to help medical 
researchers and clinicians to perform association 
studies with the use of information technologies 
(IT) within an open, integrated platform, allowing 
access to existing patient records from three dif-
ferent European clinics. More speciﬁ  cally, ASSIST 
currently integrates patient data originated from 
three gynecology clinics located in Belgium (Ghent 
University Hospital), Germany (Charité Hospital, 
Berlin) and Greece (Papageorgiou General Hospi-
tal, Thessaloniki). Each data repository has its own 
autonomous schema and captures patient informa-
tion related to CxPCa, according to the local 
clinical procedures followed. An ethical committee 
approach was obtained as appropriately from each 
site of data collection before the utilization of 
patients’ data. In addition, those data were ano-
nymised prior to their availability via the ASSIST 
platform.
Personal data included in the databases were: 
date of birth, age at presentation, place of living, 
gravidity, parity, tobacco use (cigarettes per day 
and smoking years), use of oral contraceptives 
(years), use of intrauterine contraceptive device 
(years). Data regarding cervical HPV exposure 
included the age at the date of 1st HPV testing, 
whether HPV presence was detected in each visit, 
whether a low risk or a high risk HPV type was 
detected, as well as the kind of testing (e.g. PCR, 
hybrid capture, speciﬁ  c commercial kits, etc.). PAP 
smears were used for HPV genotyping. Cytology, 
colposcopy, and—when available—histology 
results were recorded (details given in the next 
paragraph). In cases where an intervention (i.e. 
punch biopsy of the cervix, large loop excision of 
transformation zone (LLETZ), conectomy or hys-
terectomy) was necessary, the kind, the date, and 
the result of the intervention were also available. 
All data are in form of discrete categorical values, 
i.e. no vital signal and image data are included.
Furthermore, genetic test results for polymor-
phisms possibly associated with CxPCa, i.e. p53 
codon 72 polymorphisms (arginine/arginine 
omozygotes, arginine/prolin heterozygotes, pro-
lin/prolin omozygotes), MTHFR polymorhisms 
(cytocine/cytocine omozygotes, cytocine/thymine 
heterozygotes, and thymine/thymine omozygotes), 
GSTT1, GSTM1, and CYP1A1 polymorphisms 
(wild type, heterozygotes, and null genotype), were 
also considered when available. For SNP analysis, 
either PAP smear or blood sample was used.
Data recruitment from the three different busy 
clinical sites across Europe, increased number of 
patients enrolled in the project, and virtual uniﬁ  ca-
tion of these data, are all factors that increase the 
power and quality of association studies minimiz-
ing the limitations of the outcomes. At this point, 
records from 2,038 patients (more than 3,000 
visits) have been made accessible to ASSIST by 
the three clinics. Using information from these 
medical records, research studies can be imple-
mented to extract associations between CxPCa and 
viral, lifestyle and genetic factors aiming to 
advance knowledge on the origin and progress of 
the disease.
ASSIST virtually uniﬁ  es these heterogeneous 
data sources syntactically, by deﬁ  ning a common 
data schema, and semantically via a domain ontol-
ogy for precancerous and cancerous cervical 
lesions that encapsulates the appropriate medical 
knowledge to model the disease towards inferring 
its severity via the available diagnostic information 
(cytology, colposcopy and histology) and HPV 
infection results, as well as to express other dis-
ease-related information such as putative genetic 
polymorphisms associated with CxPCa, lifestyle 
and personal information. The main challenge has 
been to unify the three types of diagnostic results, 
coded according to locally used schemes, and infer 
disease severity expressed in a uniform and medi-
cally sound way. Thus, uniform coding has been 
elaborated for each type of diagnostic test result, 
so that the underlying heterogeneity in each clinic 
site is addressed. Interpretation to the limited exist-
ing standardised coding schemes is also supported 
when possible. This uniform classiﬁ  cation of exam 
results is then employed in the context of medical 
rules for the inference part of the system, so as to 
identify the disease severity.34
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2.2. Cervical cancer semantic concepts
The typical approach for diagnosis and treatment 
of precancerous cervical lesions and/or invasive 
cancer includes anamnesis, routine clinical exam-
ination, smear test sampling (cytology), disease-
speciﬁ  c clinical examination (colposcopy) and, if 
clinically necessary, biopsy sampling from suspi-
cious for cancer sites (histology). Contemporary 
medical knowledge and clinical cost-effectiveness 
dictate that where cytology and colposcopy are 
normal, no further interventions are required. On 
the most of other occasions, especially in the pres-
ence of moderate or severe cytological and/or 
colposcopical abnormalities, histology is manda-
tory in order to exclude or to verify the disease.
22 
Furthermore, HPV testing may be advised in 
certain cases and lifestyle related questions may 
be asked to the patient.
In current clinical practice there is no uniform 
way of describing cytology, colposcopy and histol-
ogy ﬁ  ndings. It was therefore realized that a need 
was eminent for common interpretation of similar 
conditions and diseases, and for common clinical 
protocols, if possible. The challenge of aggregating 
medical information lying in disperse databases, 
though not easy, could enable the reuse and exploi-
tation of existing medical data for clinical and 
research purposes.
It has to be noted that no genetic factor has been 
established so far as to be a risk factor for the 
development of cervical neoplasia; hence, genetic 
testing is not part of clinical practice for the disease. 
However, genotype information on certain poly-
morphisms may exist in medical records as part of 
research.
2.3. ASSIST coding
Towards a common interpretation of the diagnostic 
test results, a scheme for uniform coding has been 
deﬁ  ned for the crucial ﬁ  elds of cytology, colposcopy 
and histology. These test results express the sever-
ity of cervical disease although they vary in the 
level of detail and type of information. ASSIST 
introduces a uniform coding scheme for all three 
tests consisting of 4 distinct classes (Table 1): the 
ﬁ  rst one includes test results with normal ﬁ  ndings, 
the second class indicates Low Grade Cervical 
Intraepithelial Neoplasia (LCIN), the third class 
indicates High Grade Cervical Intraepithelial 
Neoplasia (HCIN) and, ﬁ  nally, the fourth class cor-
responds to Invasive Cervical Cancer. The proposed 
coding scheme (from now on referred as “ASSIST 
coding”) appears a reasonable option because: (a) 
it follows a simple index of severity of cervical 
precancerous disease, (b) it is pragmatic, and (c) it 
is closely related to clinical decision making and 
follow-up. More speciﬁ  cally, the ASSIST coding 
is closely related with the main clinical decisions 
that a physician has to make during the management 
of women with normal cervical screening results, 
precancerous lesions or invasive cancer of the 
uterine cervix.
In particular, regarding cytology results, there 
are two classification systems widely used, 
namely, the Bethesda and the Munich system 
(an extension of the Papanicolaou (PAP) classiﬁ  -
cation), parallel to the detailed description of 
ﬁ  ndings.
23–27 ASSIST cytology Code 0 includes 
normal cells, PAP I, PAP II, metaplasia, infection, 
regeneration, and atrophy. ASSIST cytology 
Code 1 includes atypia, koilocytic atypia, HPV 
alterations, ASC-US, PAP IIw, PAP IIk, PAP III, 
PAP IIID, mild dyskaryosis, mild dysplasia, 
LGSIL (Low Grade Squamous Intraepithelial 
Lesion), CIN1, AGUS, and ACG-NOS. ASSIST 
cytology Code 2 includes ASC-H, PAP IIIG, PAP 
IVa, PAP IVb, moderate dyskaryosis, severe dys-
karyosis, moderate dysplasia, severe dysplasia, 
HGSIL (High Grade Squamous Intraepithelial 
Lesion), CIN2, CIN3, AIS (Adenocarcinoma in 
situ), and AGC—favor neoplasia. Finally, ASSIST 
cytology Code 3 includes PAP V, cellular changes 
suggestive of invasive squamous carcinoma, and 
cellular changes indicative of adenocarcinoma of 
the uterine cervix and other invasive cancer.
Regarding colposcopy results, ASSIST colpos-
copy Code 0 includes within normal limits out-
come (normal—metaplasia—infection—atrophy); 
ASSIST colposcopy Code 1 includes low grade 
abnormal ﬁ  ndings; ASSIST colposcopy Code 2 
Table 1.  ASSIST coding of data derived from screening 
for cervical cancer and/or from surveillance of women 
with precancerous lesions or cervical cancer.
(a)   Normal 
(+ Within Normal Limits)
Assist code = 0
(b)   Low Grade Cervical 
Intraepithelial Neoplasia (LCIN)
Assist code = 1
(c)   High Grade Cervical
Intraepithelial Neoplasia (HCIN)
Assist code = 2
(d) Invasive Cervical Cancer Assist code = 335
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includes high grade abnormal findings; and 
ASSIST colposcopy Code 3 includes ﬁ  ndings sug-
gesting invasive cancer.
22
Similarly, for histology results, ASSIST histology 
Code 0 includes normal cervical epithelium, meta-
plasia, infection, hyperplasia, and atrophy. ASSIST 
histology Code 1 includes condyloma, coilocytic 
atypia, atypia, mild dysplasia, low grade dysplasia, 
and CIN1. ASSIST histology Code 2 includes mod-
erate dysplasia, CIN2, severe dysplasia, high grade 
dysplasia, CIN3, CIS (Carcinoma in situ) and adeno-
carcinoma in situ (AIS). Finally, ASSIST histology 
Code 3 includes invasive squamous cell carcinoma 
(SCC) and adenocarcinoma of the cervix.
Since ASSIST coding consists of 4 classes, it 
poses limitations when mapping test results 
expressed with higher level of detail. Unfortunately, 
there is no standardization related to colposcopy 
and histology results, therefore, clinics tend to use 
locally deﬁ  ned coding schemes. However, cyto-
logical results may be described using the two 
established classiﬁ  cation systems, namely, Bethesda 
and Munich, in which case they are preserved by 
ASSIST. Speciﬁ  cally, if cytological results coming 
from a speciﬁ  c clinic use either Bethesda or Munich 
classes (or a subset of them), then ASSIST will 
keep this classiﬁ  cation, in addition to the ASSIST 
mapping. However, if cytological results are 
expressed in merged Bethesda or Munich classes, 
then the ASSIST classiﬁ  cation will be used instead. 
As a result, it is optional to request and retrieve 
cytological results expressed uniformly either in 
Bethesda or in Munich (provided that the original 
records contain the necessary information) or in the 
ASSIST coding scheme. Tables 2 and 3 depict two 
examples of cytology results integration. In case 1, 
the University Hospital of Ghent uses a cytology 
classiﬁ  cation with a subset of distinct Bethesda 
classes; cytology records are therefore integrated 
in ASSIST in two ways: i) preserving Bethesda 
classiﬁ  cation and ii) mapped to ASSIST coding. In 
case 2, however, the Charité Hospital classiﬁ  es 
cytology results in merged classes from both the 
Bethesda and Munich system. Speciﬁ  cally, although 
most classes are distinct Munich classes, the HSIL 
class used (which is a Bethesda term) cannot be 
mapped to a distinct Munich class. In this case, 
integration is performed using the ASSIST coding. 
Cytology results can always be mapped to the four 
distinct ASSIST codes that are related to clinical 
decision making during management of women 
with normal cervical screening results, precancer-
ous lesions or invasive cervical cancer.
2.4. ASSIST severity index
The amount of the information collected and 
expressed by using the ASSIST coding, is ﬁ  nally 
Table 2. Mapping between the University of Ghent (U-GENT) Hospital, Bethesda and ASSIST cytology 
classiﬁ  cations.
U-GENT cytology classiﬁ  cation BETHESDA classiﬁ  cation ASSIST cytology coding
Normal Cervix Negative for intraepithelial 
lesion or malignancy
0
Reactive Changes Reactive changes 0
ASCUS ASCUS 1
LSIL (CIN1, Coilocytosis, Mild 
Dysplasia)
LSIL 1
ASC-H ASC-H 2
HSIL (CIN2, CIN3, CIS, Moderate 
Dysplasia, Severe Dysplasia)
HSIL 2
SCC (Squamous Cell Carcinoma) SCC 3
AGC-NOS Glandular atypical cells 
(NOS or specify in comments)
1
AGC-favor neoplasia Atypical glandular cells favor 
neoplasia
2
AIS AIS 2
Adenocarcinoma Adenocarcinoma 336
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represented by an index, called “Severity Index” 
(SI), which is the equivalent for the existing risk 
for cervical malignancy of the individual woman. 
This index is closely related with the main clinical 
decisions that a physician has to make during the 
management of women with normal screening 
results or with already detected precancerous 
lesions or the cervix. Individuals with normal or 
within normal limits results, independently of the 
way they have been obtained (i.e. via cytology, 
and/or colposcopy, and/or (seldom) histology), are 
basically discharged from the clinic with instruc-
tions for regular follow-up according to the local 
protocols. These women are essentially healthy 
individuals and correspond to “SI = 0.” Women 
with results that need to be followed-up earlier 
than usual and do not mandate ablation or 
excisional treatment of the altered cervical epithe-
lium (i.e. HPV-related alterations, presence of 
atypical squamous cells of unknown signiﬁ  cance, 
CIN1, satisfactory colposcopy with low grade 
abnormal ﬁ  ndings and low grade histology in 
biopsy) are encoded with “SI = 1.” Women who 
cytologically are found to have CIN2–3, women 
who have satisfactory colposcopy with high grade 
lesions, and women who had LLETZ or cone 
biopsy and histologically proven high grade cervi-
cal lesions but not stromal invasion are coded with 
“SI = 2.” Finally, women with invasive cervical 
cancer (squamous cell carcinoma or adenocarci-
noma) are coded with “SI = 3.”
In order to deﬁ  ne the SI based on the results of 
cytology, colposcopy and histology, all these 
results have to be ﬁ  rst uniﬁ  ed and interpreted in 
the ASSIST coding. Every medical record is essen-
tially associated to a patient Visit and may contain 
one or more examinations. An examination may 
be any of the diagnostic interventions, namely, 
cytology, colposcopy, histology and HPV test. The 
set of examinations that are deﬁ  ned and performed 
when a medical guideline is followed for a certain 
patient during a speciﬁ  c time period, constitute a 
Case. Patients, Cases and Visits should be identi-
ﬁ  ed in each database. It is clear that the concepts 
of Patients and Visits already exist in each database; 
however, the Case identiﬁ  cation should also be 
provided. In this context, the SI is deﬁ  ned per case 
and is derived from the results of cytology, colpos-
copy and histology that may be associated with 
(through the corresponding visits) as follows. 
ASSIST identiﬁ  es all cytology examinations in a 
case and keeps the most severe one. The same 
applies for colposcopy and histology examinations. 
Then, the SI of the case is inferred from the ﬁ  nal 
set of the three examinations according to the rules 
described in Table 4.
Severity Index distinction in 4 classes similar 
to ASSIST coding, appears to be clinically accept-
able because it is closely related to major clinical 
outcomes and subsequent major clinical deci-
sions. The SI is exclusively depended on the 
clinical results. Today, the status of a cervix is 
deﬁ  ned as: a) normal, b) with low grade lesion, 
c) with high grade lesion or d) with cancer. In this 
regard, the SI (from 0 to 3) directly corresponds 
to this stratiﬁ  cation, and therefore is considered 
to be a tool enhanced by clinical signiﬁ  cance.
Figure 1 depicts the overall data uniﬁ  cation 
scheme employed in ASSIST that leads to the 
identiﬁ  cation of the SI for each patient. The above-
mentioned semantic concepts and rules on CxPCa 
have been encoded formally and incorporated in 
Table 3. Mapping between the Charité Hospital, Munich and ASSIST cytology classiﬁ  cations.
Charité cytology classiﬁ  cation MUNICH classiﬁ  cation ASSIST cytology coding
PAP I PAP I 0
PAP II PAP II 0
PAP IIw PAP IIk PAP IIw 1
PAP III PAP III 1
PAP IIID LSIL PAP IIID 1
PAP IVa PAP IVa 2
PAP IVb PAP IVb 2
HSIL PAP IVa or PAP IVb 2
PAP V PAP V 337
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Aristotle University Clinic University of Ghent Clinic
HPV Test
HPV Test
HPV Test HPV Type
Cytology*
Cytology
Cytology*
MTHFR
MTHFR
MTHFR
Histology
Histology
Patient Case
Histology
HPV Test
Cytology*
MTHFR
Histology
+/−
1/2/3/4
Ala/Val, Val/Val, Ala/Val
Normal, CIN1/2/3, AIS,
CxCa Normal, LCIN, HCIN,
CxCa
*Internal Coding
Normal, ASCUS, LSIL,...
Wild, Hetero, Polymorhism
Normal, CIN1/2/3, SCC,
AdenoCa
*Bethesda Coding
Charité University Clinic
High, Low, No HPV
PAPI, PAPII, PAPIII,...
N/A
*Internal Coding
(merged Munich & Bethesda)
Mapping to Ontology Terms
ASSIST
Result
Unification
Severity
Index
Inference
Colposcopy
ASSIST
Cytology 0
ASSIST
Cytology 1
ASSIST
Cytology 2
ASSIST
Cytology 3
Severity
Index 0
Severity
Index 1
Severity
Index 2
Severity
Index 3
Figure 1. Heterogeneity in biomedical data related to cervical diagnostic examinations in individual patients and their virtual uniﬁ  cation.
Table 4. ASSIST medical rule and procedural logic for CxPCa Severity Index deﬁ  nition.
BEGIN
IF examination result of  Histology  OR  Colposcopy  OR  Cytology  available THEN
  IF two or more diagnostic test results exist AND difference between any two results   = 2 THEN
   Severity Index  is deﬁ  ned as the greatest index among the results
  ELSE
  IF  Histology  deﬁ  nition available THEN
  use  Histology  as  Severity Index  deﬁ  nition
  ELSE
  IF  Colposcopy  deﬁ  nition available THEN
  use  Colposcopy  as  Severity Index  deﬁ  nition
  ELSE
  use  Cytology  deﬁ  nition as  Severity Index  deﬁ  nition
  ENDIF
  ENDIF
 ENDIF
ELSE
   Severity Index  may not be deﬁ  ned
ENDIF
END
the ASSIST Cervical Cancer Ontology that is 
described in the following.
3. Results
3.1. ASSIST semantic model
The ASSIST Cervical Cancer Ontology, being the 
first one to ever semantically model CxPCa 
concepts, was designed and constructed following 
the medical knowledge elicitation phase described 
above. It encapsulates basic EHR (Electronic 
Health Record) information, examination results 
and genetic information together with the medical 
rules defined, so as to enable the mapping of 
diverse terms originated from each CxPCa data 
repository into a common schema and ﬁ  nally to 
infer the SI for CxPCa of each patient.38
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An interesting property of the ASSIST Cervi-
cal Cancer Ontology is that it provides great level 
of extensibility. The concept hierarchy is 
expanded from rather generic medical entities to 
speciﬁ  c CxPCa ones. This way, it can virtually 
incorporate any cancer domain knowledge and 
can even be further extended to other medical 
domains as well. This could provide potential 
means for representation of diseases and medical 
concepts and research on interrelation of 
diseases.
As noted in section 2.4, computation of SI is 
based in the notion of Case. It is, therefore, 
natural for the conceptual model that is built 
around the Case concept. This is directly con-
nected with the notions of Visit, Clinic, Person, 
Severity Index, and Lifestyle Choice (including 
Smoking, Parity, and Use of Contraceptives) and 
indirectly associated with others like Diagnos-
tic Examination (including Cytology, Colpos-
copy, Histology and HPV Test), Therapeutic 
Intervention, HPV Vaccination and Genetic 
Polymorphisms.
Entities constituting the ASSIST Cervical 
Cancer Ontology are essentially of two types:
−  Generic EHR entities: These are generic in the 
sense that they are not CxPCa speciﬁ  c and can 
be extracted directly from the Hospital Informa-
tion System. Included here are concepts like 
Patient, Case, Visit, Clinic, Medical Interven-
tion, Lifestyle Choice etc.
−  CxPCa-speciﬁ  c entities: These are usually sub-
classes of the previous ones and are intended to 
model knowledge useful to describe CxPCa 
disease and related factors. This type includes 
Cytology, Colposcopy, Histology, CxPCa 
Severity Index, as well as HPV and genetic 
polymorphism information.
Figure 2 depicts the major concepts of the 
ASSIST Cervical Cancer Ontology, as well as their 
associations via appropriate properties.
3.2. Rules for semantic inference
As far as reasoning is concerned, this is based on 
two types of rules, expressed as Description Logics 
Clinic
Visit
Result
Case
Person
Severity
Index
Diagnostic
Intervention
madeAtClinic
0:1
hasIntervention
“is-a” properties
Object properties
caseHasPart
0:*
hasResult
0:1
hasCase
0:*
Diagnoses
0:*
0:*
Serverity Index of
Cervical Precancerous
Disease
Serverity 0 Serverity 1 Serverity 2 Serverity 3
Figure 2. Schematic representation of the basic concepts and their relations in the ASSIST Cervical Cancer Ontology.39
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restrictions,
28 which produce inferred types for 
proper characterization of asserted knowledge. The 
ﬁ  rst type of restrictions is basically employed to 
achieve the semantic uniﬁ  cation of examination 
results in terms of the ASSIST Coding scheme. 
Figure 3 depicts the example of a restriction 
employed to infer that a cytology has indicated 
ﬁ  ndings within normal limits, i.e. ASSIST cytology  
Code = 0, using the rules as deﬁ  ned in Tables 2 and 
3. The second type of restrictions aims at the aggre-
gation of uniﬁ  ed examination results, to produce 
verdict on the SI of the corresponding case, as 
deﬁ  ned in Table 4. Patients categorized as having 
SI = 1 are inferred by employing the restriction 
depicted in Figure 4.
3.3. Implementation details
The ASSIST Cervical Cancer Ontology was devel-
oped in Protégé knowledge modeling tool,
29 while 
the knowledge representation language employed 
was OWL-DL.
30 Sesame (http://www.openrdf.
org/) and OWLIM
31 were chosen for storage and 
reasoning, respectively.
Furthermore, a simple medical-researcher ori-
ented ontology editor was developed, in order to 
ensure easy and secure maintainability and incor-
poration of new knowledge. This tool permits easy 
rule insertion and concepts/properties manipulation 
requiring no knowledge engineering expertise, 
while assuring that vital concepts and interrelations 
remain unaffected.
The ASSIST Cervical Cancer Ontology TBox 
currently consists of 163 classes, 21 object proper-
ties, 33 datatype properties and 26 equivalent class 
axioms, while current instantiation of the ontology 
ABox contains about 60,000 individuals.
3.4. Example usage scenario
Suppose a researcher wishes to investigate whether 
there is an association between the MTHFR poly-
morphism and cervical precancerous lesions. 
While planning the study, he/she consults ASSIST 
to see, if there are shared data from patients with 
LCIN, HCIN and healthy patients for whom 
MTHFR genotype data are also available. The 
ASSIST User Interface offers the option to use the 
inferred ASSIST Cervical Cancer SI to express 
LCIN or HCIN, which is deﬁ  ned on the basis of 
the medical rules explained in section 2.4. Select-
ing a query to view all patients by inferred SI, the 
user can rapidly check the type of patients for 
whom data are shared through the ASSIST infra-
structure (Fig. 5).
The user can express the severity of the disease 
through the results of cytology or colposcopy or 
histology or any combination of those. The results 
П
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П
П
П
П
П
П
П
П
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П
П
hasCytologyMunichResult {I})  
hasCytologyMunichResult {II})   
hasCytologyBethesdaResult {negative})  
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hasCytologyBethesdaResult {cellularChangesConsistentWithHerpesSimplexVirus}) 
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Figure 3. Example restriction rule employed to achieve the semantic uniﬁ  cation of cytology results that correspond to ﬁ  ndings within normal 
limits in terms of the ASSIST coding scheme.40
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ASSIST1_Severity ≡ Cervical_Cancer_Severity п
(   isDiagnosedBy
(   caseHasCollectiveResult ASSIST1_Collective_Histology_Result
) 
(
( (   caseHasCollective Result NO_Collective_Histology_Result) п 
(Case п 
п
п
(
)
)
)
)
)
(   caseHasCollectiveResult ASSIST1_Collective_Colposcopy_Result)
(   caseHasCollectiveResult NO_Collective_Histology_Result) п
(   caseHasCollectiveResult NO_Collective_Colposcopy_Result) п
(   caseHasCollectiveResult ASSIST1_Collective_Cytology_Result)
E
E
E
E
E
E
E
Figure 4. Example restriction rule employed to aggregate uniﬁ  ed examination results so as to infer SI = 1 for the corresponding case.
Figure 5. Viewing all available patients by Severity Index: On the left, all medical entities related to cervical cancer and pre cancer are 
displayed in a tree structure. The user can expand the tree items and select the type of information he/she wishes to use as search criteria. 
In this example, the user has selected Cervical Cancer Severity Code, meaning that all patients, for whom SI can be inferred, will be extracted. 
The preview of the query is shown on the top of the screen. On the right, the number of extracted records can be viewed both in table and 
graph format. For 32 patients, no diagnostic information was available; therefore, SI could not be inferred.41
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of those exams are expressed through the uniﬁ  ed 
ASSIST coding. Using combined queries, the 
researcher asks for patients with genotypic data for 
the MTHFR polymorphism and for whom the 
staging of precancerous lesions is expressed 
through cytological results coded in the ASSIST 
uniﬁ  ed cytology coding (Fig. 6). The graphical 
representation of the results indicates that the 
distribution of the MTHFR genotypes is different 
in the three stages of the disease. The user can 
Figure 6. Viewing the distribution of MTHFR genotypes in patients with different cytology results: In the current example, the user 
has selected all patients with data for the MTHFR polymorphism. Then, he/she has selected to view the MTHFR distribution of the three 
MTHFR genotypes in patients with different cytology results. A preview of the current query is shown on the top of the page. The cytology 
results are expressed with the uniﬁ  ed ASSIST cytology coding. As shown on the top of the screen, from the total of 2,032 patients the 
requested type of information exists for 975 patients.42
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continue with more queries involving additional 
patient parameters and further statistical tests on 
the extracted dataset. ASSIST offers a user friendly 
environment to express queries in a “language” 
easily understandable by the medical researcher 
and to also retrieve patient records that may use 
different internal coding schemes.
4. Discussion
Lately, there is an increasing research interest in 
genetic association studies, emphasizing in qual-
ity aspects. The potential of reusing existing 
patient data can lead to high number of samples, 
thus, increasing power of the tests, while at the 
same time reducing the cost for the implementa-
tion of such studies.
32 Several projects are under 
development, aiming to provide integration tools 
that will allow accessibility and interpretation to 
a wealth of clinical records in disperse reposito-
ries. For example, i2b2 (https://www.i2b2.org/) is 
an NIH-funded research project developing a scal-
able IT framework that will bridge clinical 
research data and the vast data banks arising from 
basic science research, in order to better under-
stand the genetic bases of complex diseases. The 
UK-founded CLEF project (http://www.clinical-
escience.org/) focuses on generic methods for the 
capture, processing, and dissemination of informa-
tion about cancer patients and their care using 
EHR data integrated with support for clinical and 
basic research in the biosciences. It aims to incor-
porate this information in formal knowledge 
management systems within a Grid framework. 
In the same fashion, the EU-funded NeuroWeb 
project (http://nuke.neurowebkc.eu/) aims to 
improve healthcare delivery related to neurosci-
ences, achieving knowledge-based, personalized 
diagnosis and therapy through vertical integration 
of existing clinical and genetic databases. It stim-
ulates the sharing of knowledge on cerebrovascular 
diseases using a Web-based platform. The Health-
e-Child project (http://www.health-e-child.org/) 
aims at developing an integrated healthcare 
platform for paediatrics, providing seamless 
integration of traditional and emerging sources of 
biomedical information, primarily focusing on 
individualized disease prevention, screening, early 
diagnosis, therapy and follow-up of paediatric 
heart diseases, inﬂ  ammatory diseases, and brain 
tumours. In most of these efforts, semantic tech-
nologies have been employed as an enabling 
technical endeavor for biomedical data integration 
and knowledge modeling. It has to be noted that, 
in such efforts, ethical and regulatory issues need 
also to be addressed in combination with privacy 
and security aspects.
ASSIST moves in a parallel course with the 
abovementioned research initiatives, aspiring that 
its platform will function as an IT tool enabling 
association studies linked with cervical cancer 
research by establishing a collaborative environ-
ment and allowing any medical group active in this 
area to use its facilities and/or contribute their own 
data/results. Cervical cancer, the second most com-
mon cancer in women, is recently subject of a 
tremendous interest by the scientists all over the 
world, especially because of the new knowledge 
concerning the causal role of HPV in the pathogen-
esis of the disease, and the new perspectives of 
disease prevention through prophylactic vaccina-
tion against viral infection. However, the interac-
tions between HPV infection, environmental factors 
and host genetic background have not been yet fully 
elucidated and still reﬂ  ect a ﬁ  eld of continuing 
research interest. To this end, ASSIST aims to offer 
a new technological solution that will virtually unify 
multiple patient record repositories (physically 
located at different laboratories, clinics and/or 
hospitals) thus, enabling researchers to utilize exist-
ing genotypic and phenotypic patient data from 
several clinics and perform association studies in a 
low-cost and time-efﬁ  cient way. Currently, a uniﬁ  ed 
CxPCa data repository has been constructed, as a 
result of the ASSIST semantic integration method-
ology described above. With regards to genetic data, 
the current version of the ASSIST Cervical Cancer 
Ontology includes genotypic information of poly-
morphisms suspected to cause cervical cancer. Such 
data are currently available in research databases 
and can directly be exploited through the ASSIST 
platform and produce association study results. 
As genomic sequencing results will become avail-
able in the following years, it is evident that the 
ASSIST Cervical Cancer Ontology has to be 
expanded to incorporate such kind of information.
Following a generic design, the ASSIST system 
may be expanded in terms of its underlying knowl-
edge model, in order to facilitate genetic associa-
tion studies for other diseases, e.g. colon cancer 
and cardiovascular diseases. As presented in this 
paper, in ASSIST the main challenge has been to 
unify diagnostic results and severity index which 
are expression of disease severity. The presented 43
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approach constitutes a paradigm for semantic inte-
gration of heterogeneous clinical data that may 
be applicable to more diseases. The ultimate goal 
for ASSIST is to foster the biomedical research 
community by providing an open, integrated and 
collaborative framework to facilitate genetic asso-
ciation studies.
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